When this drug is given intramuscularly and/or intrathecally, it should be given only to hospitalized patients, so as to provide constant supervision by a physician.
Patients with nephrotoxicity due to POLY-MxB usually show albuminuria, cellular casts, and azotemia. Diminishing urine output and a rising BUN are indications for discontinuing therapy with this drug.
Neurotoxic reactions may be manifested by irritability, weakness, drowsiness, ataxia, peripheral paresthesia, numbness of the extremities and blurring of vision. These are usually associated with high serum levels found in patients with impaired renal function and/or nephrotoxicity.
The neurotoxicity of POLY-MxB can result in respiratory paralysis from neuromuscular blockade, especially when the drug is given soon after anesthesia and/or muscle relaxants.